<p>Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.  Related Content:</p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.5157?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib</a></li> </ul>

Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

<p>Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD.  Related Content:</p> <ul> <li><a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.5157?utm_source=podcast_platforms&amp;utm_medium=referral&amp;utm_campaign=related_article_links" rel="noopener noreferrer">Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib</a></li> </ul>

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

Share Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Sign up to save your podcasts

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

More shows like JAMA Oncology Author Interviews

NEJM This Week

Journal of Clinical Oncology (JCO) Podcast

JAMA Clinical Reviews

JAMA Pediatrics Editors' Summary

ASCO Daily News

The Daily

Up First from NPR

JAMA Cardiology Author Interviews

JAMA Dermatology Author Interviews

JAMA Internal Medicine Author Interviews

JAMA Neurology Author Interviews

JAMA Ophthalmology Author Interviews

JAMA Otolaryngology–Head & Neck Surgery Author Interviews

JAMA Pediatrics Author Interviews

JAMA Psychiatry Author Interviews

JAMA Medical News

ASCO Guidelines

JAMAevidence Care at the Close of Life

JAMAevidence The Rational Clinical Examination

JAMAevidence Users' Guides to the Medical Literature

JAMA Network Open Conversations

Coronavirus (COVID-19) Q&A

JAMAevidence JAMA Guide to Statistics and Methods

The Rest Is History

JAMA Health Forum Conversations

JAMA Author Interviews

Bad Rap: The Case Against Diddy